Listed companies are obliged by law to publish without delay news of all company occurrences that could influence the share price significantly (Article 17 of the European Market Abuse Regulation (MAR)). We are committed to transparency and want to ensure that all capital market participants have access to key information about our company as quickly as possible, and thus prevent insider dealing due to any information asymmetry.
Directors' DealingsRead More
Voting Rights NotificationsRead More
Voting Rights Notifications
Related NewsView All News
Two new strategic drug discovery collaborations aim at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities.